Skip to main content
OpenTrials
Completed

NCT Number: NCT03977831

Study Comparing Open Radical Cystectomy With Robot-assisted Cystectomy in Patients With Bladder Cancer

The purpose of the study to compare two established methods of radical cystectomy (RC) in patients with bladder cancer. The participants will be treated under conditions in alignment with up-to-date guidelines and care. We wish to investigate whether it is feasible to compare the two methods under conditions of the highest methodological quality.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Department of Urology, Rigshospitalet

Copenhagen, Denmark

About this study

Radical cystectomy (RC) is a comprehensive surgery including pelvic lymph node dissection and urinary diversion. The surgery is originally performed as an open procedure (ORC) but with advances in technology the procedure is now also offered as a robot-assisted laparoscopic procedure (RARC). It remains questionable if RARC is superior to ORC in terms of surgical outcomes.

Several studies have described outcomes following RARC of which most are comparative studies with only five studies being randomized controlled trials (RCTs). Overall, significant differences in operating room time, estimated blood loss, time to flatus and bowel movement as well as use of morphine sulfate equivalents in favor of RARC has been demonstrated with the exception of operating room time. However, no studies have demonstrated a significant reduction in risk of 30- or 90-day complication rates between ORC and RARC. The RCTs have not been blinded, and therefore may be subject to bias in terms of expectations from patients and care providers. Also, in the already conducted RCTs of ORC versus RARC the urinary diversion has been done extracorporally. Today, it is possible to conduct the whole procedure of RARC intracorporally (iRARC), potentially reducing the surgical stress further. Lastly, the previously conducted RCTs have not consequently been managed under an Enhanced Recovery After Surgery (ERAS) setup. Currently, a multicenter study comparing ORC with RARC is recruiting in the United Kingdom in which the patients are treated with iRARC and under an ERAS setup. The present study will compare the two methods blinded for the participants and all health care providers involved in the postoperative care from the time the patient exits the operating room (OR). Blinded studies in surgery are rare but in gastrointestinal surgery, a blinded study of open versus laparoscopic colonic resection has demonstrated to be feasible and thus we believe that such study must be feasible in an RC setting.

Participants will be randomized 1:1 to either ORC or RARC. Blinding: The study is blinded for the patient and for the group of nurses and doctors that will be responsible for the postoperative care. The postoperative care will be managed by members of the bladder cancer team other than the operating surgeon, and OR staff will not be involved in the postoperative care. The abdominal wound will be bandaged to hide the wounds from both an open and laparoscopic procedure. The blinding will be maintained until discharge from hospital.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • age> 18
  • non-metastatic disease
  • fit for both ORC and RARC
  • Patient-selected urinary diversion: ileal conduit

Exclusion criteria

  • if not able to speak/understand Danish
  • not able to cooperate for fully informed consent
  • need for extensive concomitant surgery (i.e. nephroureterectomy)
  • prior down staging chemotherapy (prior neoadjuvant chemotherapy accepted)
  • prior radiation therapy
  • prior major extensive abdominal or pelvic surgery
  • prior peritonitis
  • conditions contraindicating extended Trendelenburg's position

Treatment and study plan

Radical Cystectomy

Procedure

Participants are randomly and blinded assigned

Primary outcomes

  1. Participants blinded at discharge

    Time frame: 12 months

    Number of patients that was not unblinded at discharge

Secondary outcomes

  1. Length of Stay (LOS)

    Time frame: 12 months

    Duration (days) of primary hospitalization. From the date of admission until the date of discharge from hospital.

  2. Days Alive and Out of Hospital (DAOH)

    Time frame: 90 days from surgery

    Number of days alive and out of hospital within 90 days from surgery

  3. 30-day complication rate

    Time frame: 30 days after surgery

    Complication rate (Clavien-Dindo)

  4. 90-day complication rate

    Time frame: 90 days after surgery

    Complication rate (Clavien-Dindo)

  5. Readmission rate

    Time frame: 90 days after surgery

    Number of readmissions

  6. Quality of Life (QoL): EORTC QLQ-C30

    Time frame: 90 days after surgery

    Registration of differences in QoL. European Organization for Research and Treatment of Cancer 30-item core quality of life questionnaire (EORTC QLQ-C30 (scale range 0-100, a higher score indicating better quality of life))

  7. Quality of Life (QoL): EORTC QLQ-BLM30

    Time frame: 90 days after surgery

    Registration of differences in QoL. European Organization for Research and Treatment of Cancer quality of life questionnaire for patients with muscle invasive bladder cancer (QLQ-BLM30 (scale range 0-100, a higher score indicating increase in symptom burden)) will be used.

  8. Blood loss

    Time frame: 4 days after surgery

    Both estimated as well as calculated/hidden blood loss

  9. Use of opioids

    Time frame: until diacharge or up to 90 days, whichever comes first

    Use of opioids, mg total postoperatively

Sponsors and collaborators

Lead sponsor

Rigshospitalet, Denmark

Other

Registry information

Official study title

A Controlled Blinded Randomized Feasibility Study of Open Radical Cystectomy (ORC) Versus Robot-Assisted Radical Cystectomy With Intracorporal Urinary Diversion (iRARC) Under an Enhanced Recovery After Surgery (ERAS) Setup

Important dates

Study start
2019
Primary completion
2020
Study completion
2021
First posted
Jun 6, 2019
Registry last updated
Jan 26, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.